A biopharmaceutical company developing therapeutics for treating age-related diseases.
On January 1, 2017 resTORbio completed their series A funding round with $25 million in funding from PureTech Health.
On November 30, 2017 resTORbio completed their series B funding rounds with $40 million in funding from OrbiMed (lead investor), Rock Springs Capital, Recharge Capital, Quan Capital, Nest.Bio Ventures, and Fidelity Management and Research Company.